Expression of PD-1 on CD4(+) T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer

Recent success of using agents inhibiting the major immune check point, programmed cell death-1 (PD-1) pathway, offers a great promise for effective cancer therapy. Two blocking antibodies for PD-1, nivolumab and pembrolizumab have recently been approved for treating advanced recurrent non-small cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Hong, Liu, Xin, Zhang, Jianhong, Rice, Shawn J., Wagman, Matthias, Kong, Yaxian, Zhu, Liuluan, Zhu, Junjia, Joshi, Monika, Belani, Chandra P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302910/
https://www.ncbi.nlm.nih.gov/pubmed/27191652
http://dx.doi.org/10.18632/oncotarget.9316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302910/
https://www.ncbi.nlm.nih.gov/pubmed/27191652
http://dx.doi.org/10.18632/oncotarget.9316

Ejemplares similares